
MoonLake Immunotherapeutics: updates and filings
Price
$11.07
November 20, 2026Market cap $942M
What Ploutos Investor adds for MoonLake Immunotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
September 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Sep 30, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 10, 2026Shares registered for employeesFormS-8
- Aug 10, 2026Shelf registration for future offeringsFormS-3ASR
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 15, 2026Other material eventsForm8-K
- Jun 29, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 25, 2026Material agreement enteredForm8-K
- Jun 22, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 9, 2026Officer or director change, shareholder voteForm8-K
- Jun 1, 2026Material agreement enteredForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 21, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Apr 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 23, 2026Material agreement entered, results of operations, new material financial obligation, officer or director change, Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Sep 30, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 10, 2026 | S-8 | Shares registered for employees | Document |
| Aug 10, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 15, 2026 | 8-K | Other material events | Document |
| Jun 29, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 25, 2026 | 8-K | Material agreement entered | Document |
| Jun 22, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 9, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 1, 2026 | 8-K | Material agreement entered | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 21, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 23, 2026 | 8-K | Material agreement entered, results of operations, new material financial obligation, officer or director change, Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 28, 2020.
The full analysis
What do MoonLake Immunotherapeutics's filings show?
The filings are where every one of MoonLake Immunotherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.